Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical stage specialty pharmaceutical company ...

Download Palmoplantar Keratoderma Sample report to know in detail about the Palmoplantar Keratoderma treatment market @ Palmoplantar Keratoderma Therapeutic Assessment Table of Content 1.

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) ("Quoin" or the "Company"), a late clinical stage specialty pharmaceutical company focused on rare and orphan ...

One of the most significant moments in the evolutionary journey of life on this planet was the transition from water to land.

April 2, 2025 Quoin Pharmaceuticals announced positive clinical data from its ongoing Investigator Pediatric Netherton Syndrome study. After six months of treatment with QRX003, significant ...

The release of this video comes as Quoin continues to advance its lead product candidate, QRX003, in multiple pivotal clinical trials for the treatment of Netherton Syndrome. Recently reported data ...

撰文丨王聪编辑丨王多鱼排版丨水成文脱发影响着全球数百万人，对生活质量及心理健康造成重大影响。尽管头发稀疏的情况很常见，但促进头发生长的有效策略仍难以捉摸。2025 年 8 月 15 ...

Methods: We describe a patient with a recessively inherited arrhythmogenic dilated cardiomyopathy with left and right ventricular involvement, epidermolytic palmoplantar keratoderma, and woolly hair.

Quoin’s innovative pipeline comprises four products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling ...

Quoin’s innovative pipeline comprises four products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling ...